Profile data is unavailable for this security.
About the company
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
- Revenue in USD (TTM)46.38m
- Net income in USD-36.47m
- Incorporated2012
- Employees69.00
- LocationCidara Therapeutics Inc6310 Nancy Ridge Dr Ste 101SAN DIEGO 92121-3209United StatesUSA
- Phone+1 (858) 752-6170
- Fax+1 (302) 655-5049
- Websitehttps://www.cidara.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey Medical Corp | 80.00m | -4.16m | 54.65m | 58.00 | -- | 6.00 | -- | 0.6832 | -0.3095 | -0.3095 | 4.13 | 0.6498 | 0.985 | 2.27 | 4.28 | 1,379,276.00 | -5.12 | -- | -17.85 | -- | 66.22 | -- | -5.20 | -- | 0.9357 | 0.4049 | 0.5773 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Carisma Therapeutics Inc | 15.07m | -81.22m | 55.25m | 107.00 | -- | 5.07 | -- | 3.67 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 55.48m | 8.00 | -- | 0.6829 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 55.73m | 14.00 | -- | 2.00 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 56.86m | 117.00 | -- | 0.242 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 57.86m | 26.00 | -- | 0.5501 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Cidara Therapeutics Inc | 46.38m | -36.47m | 57.89m | 69.00 | -- | -- | -- | 1.25 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 58.45m | 110.00 | -- | -- | -- | 73.33 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 59.36m | 41.00 | -- | 0.5365 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| LAVA Therapeutics NV | 12.54m | -28.59m | 59.41m | 37.00 | -- | 1.17 | -- | 4.74 | -1.07 | -1.07 | 0.4668 | 1.93 | 0.107 | -- | 9.09 | 338,837.80 | -24.40 | -- | -28.91 | -- | 79.64 | -- | -228.02 | -- | -- | -- | 0.108 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 60.37m | 82.00 | -- | 0.7545 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 60.96m | 179.00 | -- | 0.8489 | -- | 1.86 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Calcimedica Inc | 0.00 | -14.94m | 61.05m | 14.00 | -- | 3.54 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| Curis Inc | 9.81m | -47.73m | 61.06m | 48.00 | -- | 6.45 | -- | 6.22 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Data as of Jun 04 2024. Currency figures normalised to Cidara Therapeutics Inc's reporting currency: US Dollar USD
24.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 343.06k | 7.52% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 166.42k | 3.65% |
| Medical Strategy GmbHas of 29 Feb 2024 | 134.66k | 2.95% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 127.75k | 2.80% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 98.13k | 2.15% |
| Alethea Capital Management LLCas of 31 Mar 2024 | 79.93k | 1.75% |
| Point72 Asset Management LPas of 31 Mar 2024 | 62.50k | 1.37% |
| Geode Capital Management LLCas of 31 Mar 2024 | 41.91k | 0.92% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 35.11k | 0.77% |
| Schonfeld Strategic Advisors LLCas of 31 Mar 2024 | 27.60k | 0.61% |
More ▼
Data from 29 Feb 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
